Compounds > niacin
Page last updated: 2024-10-19

niacin and HIV-Associated Lipodystrophy Syndrome

niacin has been researched along with HIV-Associated Lipodystrophy Syndrome in 4 studies

Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.

HIV-Associated Lipodystrophy Syndrome: Defective metabolism leading to fat maldistribution in patients infected with HIV. The etiology appears to be multifactorial and probably involves some combination of infection-induced alterations in metabolism, direct effects of antiretroviral therapy, and patient-related factors.

Research Excerpts

ExcerptRelevanceReference
" Dyslipidemia in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis may improve with use of statins, fibrates, niacin, and thiazolidinediones, but the data are presently very limited."4.82Management of dyslipidemia in patients with complicated metabolic syndrome. ( Davidson, MH, 2005)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fessel, WJ1
Follansbee, SE1
Rego, J1
Davidson, MH1
Samson, SL1
Pownall, HJ1
Scott, LW1
Ballantyne, CM1
Smith, EO1
Sekhar, RV1
Balasubramanyam, A1
Oh, J1
Hegele, RA1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Diet/Exercise, Niacin, Fenofibrate for HIV Lipodystrophy[NCT00246376]221 participants (Actual)Interventional2004-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

HDL-C

HDL-C (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Interventionmg/dl (Mean)
Group 1 - Usual Care37.1
Group 2 - Diet/Exercise Only38.7
Group 3 - Diet/Exercise + Fenofibrate40.7
Group 4 - Diet/Exercise + Niacin41.8
Group 5 - Diet/Exercise + Fenofibrate + Niacin44.8

Non-HDL-C

non-HDL-C (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Interventionmg/dl (Mean)
Group 1 - Usual Care162.2
Group 2 - Diet/Exercise Only165.4
Group 3 - Diet/Exercise + Fenofibrate145.8
Group 4 - Diet/Exercise + Niacin154
Group 5 - Diet/Exercise + Fenofibrate + Niacin137.1

Total Cholesterol

Total cholesterol (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Interventionmg/dL (Mean)
Group 1 - Usual Care195.6
Group 2 - Diet/Exercise Only200.1
Group 3 - Diet/Exercise + Fenofibrate184
Group 4 - Diet/Exercise + Niacin190.8
Group 5 - Diet/Exercise + Fenofibrate + Niacin178.4

Total Cholesterol : HDL-C Ratio

Total cholesterol : HDL-C ratio: Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Interventionratio (Mean)
Group 1 - Usual Care5.2
Group 2 - Diet/Exercise Only5.1
Group 3 - Diet/Exercise + Fenofibrate4.5
Group 4 - Diet/Exercise + Niacin4.6
Group 5 - Diet/Exercise + Fenofibrate + Niacin4

Triglycerides

Triglycerides (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Interventionmg/dL (Mean)
Group 1 - Usual Care199
Group 2 - Diet/Exercise Only216.9
Group 3 - Diet/Exercise + Fenofibrate155.1
Group 4 - Diet/Exercise + Niacin177.6
Group 5 - Diet/Exercise + Fenofibrate + Niacin135.6

Body Composition

"Body cell mass (kg)~Fat mass (kg)" (NCT00246376)
Timeframe: Measured at 24 weeks

,,,,
Interventionkg (Mean)
Body cell massFat mass
Group 1 - Usual Care59.636.8
Group 2 - Diet/Exercise67.337.5
Group 3 - Diet/Exercise + Fenofibrate66.635.8
Group 4 - Diet/Exercise + Niacin67.137.7
Group 5 - Diet/Exercise + Fenofibrate + Niacin68.236.2

Insulin Sensitivity

Adiponectin (micrograms/ml) (NCT00246376)
Timeframe: Measured at 24 weeks

,,,,
Interventionmicrograms/ml (Mean)
Fasting insulinHOMA-IRInsulin sensitvity indexAdiponectin
Group 1 - Usual Care8.71.923.547.12
Group 2 - Diet/Exercise Only6.71.384.956.04
Group 3 - Diet/Exercise + Fenofibrate9.52.023.815.24
Group 4 - Diet/Exercise + Niacin11.92.762.8811.01
Group 5 - Diet/Exercise + Fenofibrate + Niacin10.32.382.3810.34

Reviews

2 reviews available for niacin and HIV-Associated Lipodystrophy Syndrome

ArticleYear
Management of dyslipidemia in patients with complicated metabolic syndrome.
    The American journal of cardiology, 2005, Aug-22, Volume: 96, Issue:4A

    Topics: Clofibric Acid; Fatty Liver; HIV-Associated Lipodystrophy Syndrome; Humans; Hydroxymethylglutaryl-Co

2005
HIV-associated dyslipidaemia: pathogenesis and treatment.
    The Lancet. Infectious diseases, 2007, Volume: 7, Issue:12

    Topics: Anticholesteremic Agents; Diet; HIV-Associated Lipodystrophy Syndrome; Humans; Hydroxymethylglutaryl

2007

Trials

2 trials available for niacin and HIV-Associated Lipodystrophy Syndrome

ArticleYear
High-density lipoprotein cholesterol is low in HIV-infected patients with lipodystrophic fat expansions: implications for pathogenesis of fat redistribution.
    AIDS (London, England), 2002, Sep-06, Volume: 16, Issue:13

    Topics: Adipose Tissue; Alkynes; Anti-HIV Agents; Benzoxazines; Body Composition; Cholesterol, HDL; Cyclopro

2002
Heart positive: design of a randomized controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia.
    Contemporary clinical trials, 2006, Volume: 27, Issue:6

    Topics: Adult; Antiretroviral Therapy, Highly Active; Combined Modality Therapy; Diet, Fat-Restricted; Exerc

2006